Mycophenolate Mofetil in Combination with Steroids for Treatment of C3 Glomerulopathy: A Case Series
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol.13, no.3, pp.406-413, 2018 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 13 Issue: 3
- Publication Date: 2018
- Doi Number: 10.2215/cjn.09080817
- Journal Name: CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.406-413
- Keywords: glomerular disease, complement, mycophenolate mofetil, Humans, Mycophenolic Acid, creatinine, Complement Membrane Attack Complex, Retrospective Studies, Follow-Up Studies, Universities, Immunosuppressive Agents, glomerulonephritis, proteinuria, immunosuppression, Recurrence, Registries, HEMOLYTIC-UREMIC SYNDROME, DENSE DEPOSIT DISEASE, COMPLEMENT FACTOR-H, MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS, ECULIZUMAB, MUTATIONS, ACTIVATION, CFHR5
- Istanbul University Affiliated: Yes
Abstract
Background and objectives C3 glomerulopathy is a form of complement-mediated GN. Immunosuppressive therapy may be beneficial in the treatment of C3 glomerulopathy. Mycophenolate mofetil is an attractive treatment option given its role in the treatment of other complement-mediated diseases and the results of the Spanish Group for the Study of Glomerular Diseases C3 Study. Here, we study the outcomes of patients with C3 glomerulopathy treated with steroids and mycophenolate mofetil.